BrainStorm Cell Therapeutics Presents New Analyses From NurOwn’s Phase 3 ALS Trial At The 21st Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from NurOwn's